Search This Blog

Friday, October 4, 2024

Bavarian Nordic’s Mpox Shot Shows Antibody Responses Wane After 6 to 12 Months: Study

 

While a JAMA study found a decline in mpox antibody responses after vaccination, a University of Oxford expert cautioned that there is still not enough evidence to determine if this decline also leads to waning protections.

The antibody response from Bavarian Nordic’s mpox vaccine Jynneos appears to weaken six to 12 months after inoculation, raising questions about its use in conferring lasting protection against the virus, according to a research letter published Thursday in the Journal of the American Medical Association.

“Our data suggest that protective immunity may be waning in individuals who were vaccinated with this vaccine in 2022,” study corresponding author Dan Barouch said in a statement.

The observational study involved 45 adults who were given either one or two doses of Jynneos. Three patients who had been diagnosed with mpox infection were also included to serve as comparators. Results showed that in people who were given two vaccine doses, titers of antibodies targeting mpox-related antigens peaked three weeks after the jab but declined to just barely above baseline levels at 12 months.

A similar trend was reported in those who were given just one Jynneos dose—with antibody titers peaking at three weeks—though the overall elicited immune response was weaker.

The researchers pointed out that three months after Jynneos vaccination, titers of mpox serum neutralizing antibodies were “minimal,” regardless of whether study participants received one or two doses. Meanwhile, in patients with confirmed infections, serum neutralizing antibody levels remained high at three months and persisted through nine months.

“These data suggest that protective immunity may be waning in individuals who were vaccinated with MVA-BN (Jynneos) in 2022 and that boosting may be required to maintain robust levels of protective immunity,” the researchers wrote, while noting that their conclusions are limited by the study’s small sample size and observational design.

Jake Dunning, senior research fellow at the University of Oxford’s Pandemic Sciences Institute, said in an expert reaction letter that while the Thursday study is important in that it helps “improve our understanding of real-life use” of new vaccines, it is also “just one piece of a quite complicated jigsaw when it comes to understanding vaccine effectiveness.”

The waning antibody titers after vaccination has long been known and is even predictable, Dunning pointed out. However, the JAMA study “does not provide proof that antibody waning results in waning protection against mpox infection or severe mpox disease in real life,” He wrote, noting that further studies are needed to better elucidate the real-life trajectory of not only a vaccine’s antibody response but also of its overall protective effect.

Despite these emerging questions about Jynneos’ long-term effectiveness, Bavarian Nordic will likely continue to enjoy the mpox outbreak windfall that analysts have predicted. Jefferies analyst Peter Welford wrote in a note to investors that the company’s value “as a standalone vaccine play is underappreciated.”

Welford contends that Bavarian Nordic will “remain firmly profitable” in the coming months and beyond as it reaps various milestones and other payments from Jynneos-related deals. The company last week entered into an agreement with UNICEF to deliver one million doses of the vaccine, which the biotech has pledged that it will make available for supply by the end of the year.

In August 2024, Bavarian Nordic received an order for 175,420 doses of Jynneos from the European Commission’s Health Emergency Preparedness and Response Authority, which will donate the vaccines to the Africa Centers for Disease Control.

https://www.biospace.com/drug-development/bavarian-nordics-mpox-shot-shows-antibody-responses-wane-after-6-to-12-months-study

Blowout Payrolls: Sept 254K Jobs Soar Above Highest View, Jobless Rate Drops, Wages Spike

 It turns out that Powell's "emergency" 50bps rate cut was - drumroll - another major mistake by the Fed.

Moments ago, the BLS reported that at a time when prevailing consensus was for jobs to continued their recent downward slide sparked by the near-record annual jobs revision, in September the US actually added a whopping 254K jobs, the biggest monthly increase since March...

... and above the highest estimate (which as we noted last night was from Jefferies at 220K); in fact, the number was a 4-sigma beat to the median estimate!

Some context: as UBS notes, the moving six-month average on nonfarm payrolls is 167k. The estimate is that 150k is about consistent with a return of the economy to trend growth. Which means that inflation is about to come back with a vengeance, just as the Fed launches its easing cycle.

Remarkably, while payrolls jumped by the most in half a year, the number of employed people also surged, rising by a whopping 430K, also the biggest one-month jump since March.

It wasn't just the payrolls, however, which came in far stronger than estimates: the unemployment rate also came in stronger than expected, and thanks to the jump in employed workers coupled with the decline in unemployed workers (from 7.115MM to 6.834MM), it dropped from 4.2% to 4.1% (and down from 4.3% two months ago which spared the entire recession panic).

And here is the rub, because in a vacuum the super strong jobs numbers would have been fantastic, the only issue is that they come as the Fed launches an easing cycle and as wages are once again rising as we have warned for the past 3 months. Indeed, in September, the average hourly earnings rose 0.4% sequentially, beating the estimate of 0.3%, while on an annual basis, wage growth was 4.0%, up from an upward revised 3.9% and beating the 3.8% estimate.

Developing

https://www.zerohedge.com/markets/blowout-payrolls-sept-254k-jobs-soar-above-highest-estimate-unemployment-rate-drops-and

EU Slaps Up To 45% Tariff On Chinese-Made EVs As "Economic Cold War" Risks Soar

 Bloomberg reports that EU member states have voted to slap tariffs of up to 45% on Chinese-made electric vehicles, ignoring warnings from some members that this dangerous move risks sparking an "economic cold war" with Beijing. 

The European Commission, the bloc's executive arm, recently concluded its anti-subsidy investigation into Chinese imports of battery electric vehicles. The findings supported the Commission's move to implement the duties, which would last for five years.

Sources familiar with the voting told Bloomberg that ten member states voted in favor of the duties, while Germany and four others voted against - and 12, including Spain, abstained. 

The new duty rate will be as high as 35% for foreign EV manufacturers exporting from China. There is already an existing 10% duty, which means the rate for some foreign EVs imported into the bloc could be as high as 45%. We have provided additional color on the rates here.

The Commission released this statement:

Today, the European Commission's proposal to impose definitive countervailing duties on imports of battery electric vehicles (BEVs) from China has obtained the necessary support from EU Member States for the adoption of tariffs. This represents another step towards the conclusion of the Commission's anti-subsidy investigation.

In parallel, the EU and China continue to work hard to explore an alternative solution that would have to be fully WTO-compatible, adequate in addressing the injurious subsidization established by the Commission's investigation, monitorable and enforceable.

A Commission Implementing Regulation including the definitive findings in the investigation must be published in the Official Journal by 30 October 2024, at the latest.

As we've previously noted, the duties are part of an anti-subsidy investigation launched earlier this year by the Commission. About 100 firms were investigated. The big finding included market-distorting subsidies across China's entire EV supply chain.

Meanwhile, the bloc has been actively pushing far-left climate change policies to de-growth its economy. The entire bloc is a mess with recession threats emanating from Germany as its automotive manufacturing industry stalls

Former European Central Bank President Mario Draghi warned last month that "China's state-sponsored competition" threatened member states. Last year, the EU traded 739 billion euros ($815 billion) with China. 

Earlier, Hungarian Prime Minister Viktor Orban said the EU tariffs on China could spark an "economic cold war"... 

European carmakers, including Mercedes-Benz, Stellantis, BMW, and Volkswagen, all have a massive footprint in China that could be jeopardized if Beijing retaliates. 

But hold up, wait a second. Haven't far-left Western leaders, including many in the US, called Trump's tariff plans against China 'terrible'? Hypocrisy at its finest. 

https://www.zerohedge.com/economics/eu-slaps-45-tariff-chinese-made-evs-economic-cold-war-risks-soar

Recordati to acquire worldwide rights to Sanofi’s antibody Enjaymo

 Recordati has reached an agreement with Sanofi for acquiring the worldwide rights to Enjaymo, the only approved treatment specifically targeting cold agglutinin disease (CAD), a rare B-cell lymphoproliferative disorder.

The terms of the acquisition include an upfront payment of $825m from Recordati to Sanofi, plus additional milestone payments of up to $250m contingent on sales performance.

This strategic move is set to enhance Recordati's rare diseases franchise and address a critical unmet medical need.

The humanised monoclonal antibody Enjaymo is indicated to treat haemolysis in adults with CAD.

With approvals from the US Food and Drug Administration (FDA), European Commission, and the Japanese Ministry of Health, Labour and Welfare in 2022, Enjaymo offers a chronic intravenous treatment for this rare condition.

Over the last 12 months as of August 2024, Enjaymo generated revenue of approximately €100m ($110m) and is projected to generate more than €150m in financial year 2025, with peak sales potentially reaching €250-300m.

Enjaymo's targeted mechanism of action inhibits the C1s in the classical complement pathway, preventing the abnormal breakdown of red blood cells.

The approval of Enjaymo by the FDA in February 2022 marked a significant milestone as the first and only treatment aimed at reducing the need for red blood cell transfusions in adults with CAD.

Subsequent approvals in Japan and Europe further established its role in treating this rare disease, with the EMA maintaining its orphan designation.


https://finance.yahoo.com/news/recordati-acquire-worldwide-rights-sanofi-103313560.html

Nondisclosure: Vaccine Ad Blitz Sidestepped Transparency Rules

 “A bun in the toaster oven,” a woman exclaims off-camera, handing an ultrasound image to family members who erupt into tearful emotion over the news. “Oh my God!” 

The touching baby announcement video then gets down to business as text appears on the screen amidst the ongoing celebration, suggesting the best way to stay alive for this joyous birth is by becoming vaccinated against COVID-19. “Why will you get vaccinated? …  Because some people you just want to meet in person.” 

It closes with the tagline: “Science can make this possible. Only you can make it real.” 

The evocative 2021 television spot was funded by Pfizer just as the pharmaceutical giant was rolling out its COVID-19 vaccine. The spot may have seemed like any other pharmaceutical advertisement. But there was something missing. The ad, and many others like it financed by vaccine manufacturers, did not include any of the typical disclaimers about risks associated with vaccines, nor any disclosures that they had not yet received Food and Drug Administration approval.

AP
Most early vaccine ads did not include the typical disclosures about risks, incluidng those for pregnant women.

Although Pfizer and other pharmaceutical companies were operating under a special Emergency Use Authorization (EUA) that allowed them to sell their COVID vaccines without going through the traditional testing and approval process, that authorization explicitly required vaccine ads to include a prominent warning that the medicines had not been fully tested for potential risks.

A RealClearInvestigations review of ads that ran tens of thousands of times during the pandemic found that the major vaccine companies routinely exploited a regulatory loophole to skirt those marketing rules while embarking on massive paid media campaigns to sell the COVID-19 vaccines. By casting their spots as public service announcements – promoting the idea that people should get vaccinated, rather than a company’s specific product – drug companies claimed the disclosure requirements did not apply. 

As a result, the required disclosure about the vaccine operating under emergency approval rarely appeared in any of the ads, even as many employers, including the federal government, required tens of millions of Americans to get vaccinated. 

“It’s an advertising laundering operation,” said Aaron Kheriaty, a bioethicist and fellow at the Ethics and Public Policy Center. The ads “violate the spirit of the EUA, if not the letter of the law.”

The ad blitz was plastered across television and social media and later celebrated by drug industry insiders as one of the most effective pharmaceutical outreach campaigns of all time. The flood of ads not only promoted Pfizer and Moderna’s products but helped influence public opinion, transforming an industry once viewed as driven by greed into altruistic heroes stepping up to solve a health crisis with no ulterior motives. 

AP
A billboard displays Pfizer's "Science Will Win" COVID-19 slogan.

WPP, the advertising conglomerate that crafted Pfizer’s “Science Will Win” ad campaign during the pandemic, was clear about the motivation when speaking to a trade outlet. “‘Science Will Win’ campaign was about changing the perception that pharmaceutical companies profited from health and from sickness,” Claire Gillis, the international chief executive officer of WPP Health Practice, boasted to The Drum, a marketing industry outlet.

Yet the role of the COVID-19 vaccine ads, which widely shaped public opinion and galvanized support for the drug industry, remains largely unexplored. Critics say it is another example of rules for pharmaceutical companies that were tossed to the wayside as maximalist policies swept through society. Online censorship, vaccination mandates, school closings, general lockdowns, and other draconian restrictions were imposed on citizens, while drug companies poised to reap unprecedented multi-billion dollar profits were given unusual and largely unscrutinized leeway. 

The attorneys general of Texas and Kansas have accused Pfizer of widely misleading the public on the effectiveness of its vaccine. Both states contend that the company violated rules that bar pharmaceutical firms from deceptive messaging, though their lawsuits largely focus on statements by company officials. Pfizer has denied that it misrepresented the vaccine and said in court documents that it is “immune” from claims since the company was acting under authorization from the federal government.

These so-called “direct-to-consumer” drug ads are a contentious area of public health. The United States and New Zealand are the only countries that permit such ads. A study from the Government Accountability Office found that from 2016 through 2018, drug manufacturers spent $17.8 billion on direct-to-consumer ads for just 553 drugs, almost all of which were brand name. Experts have sharply criticized the ads for misleading patients and encouraging many to seek out medications that are not clinically appropriate. 

The tsunami of drug ads began in 1997 when Congress lifted previous restrictions and allowed pharmaceutical ads as long as they contained a summary of the risks of each product at the end of the commercial. This has given many ads a whiplash quality, as sunny visions of a medicine’s benefits are followed by a parade of horribles regarding common side effects ranging from hallucinations and nausea to strokes, suicidal ideation, and even heart attacks. 

AP
Pfizer sidestepped FDA rules regarding disclosure through "unbranded" vaccine campaigns.

However, COVID ads from Pfizer that ran nationally during the early rollout of the vaccine contained no basic disclosure, despite the fact they were marketing a drug that had enhanced disclosure requirements. The risks around myocarditis and other heart issues were not acknowledged in spots, nor were the relative lack of benefits for young, healthy individuals with prior infection immunity.

The most glaring omission, however, was the lack of disclosure that the vaccines had not yet received FDA approval. Under the emergency approval to Pfizer and Moderna, issued in December 2020, both pharmaceutical firms were required to remind viewers of the EUA status of the vaccines in any paid media. It stated that “all descriptive printed matter, advertising, and promotional material” relating to the vaccine must “clearly and conspicuously” state that “this product has not been approved or licensed by FDA” and was authorized only under the emergency use declaration.

Those disclosures were almost nowhere to be found in countless advertisements that appeared over the ensuing months of the pandemic, as Americans faced widespread coercion to receive the shot. 

In a response to a request for comment, a Pfizer spokesperson claimed that the ads were “unbranded campaigns,” and thus, no disclosures were required. Moderna provided a similar explanation. “As this was a non-branded disease education campaign EUA disclosures were neither necessary nor appropriate,” said a company spokesperson. 

In other words, although both vaccine firms poured vast resources into marketing and advertising the vaccine, they did not mention the official brand names – Pfizer’s COMIRNATY and Moderna’s SpikeVax – and therefore, under this interpretation of the rules, neither the routine direct-to-consumer disclosures nor the EUA disclosures applied. 

That justification strikes some medical ethics experts as pure sophistry. 

LinkedIn
Dr. Martin Kulldorff says even unbranded campaigns should have accompanying warnings.

“Since the COVID vaccines were approved under EUA, even unbranded ads should have carried the required warning,” noted Dr. Martin Kulldorff, a biostatistician and infectious disease epidemiologist, and critic of many vaccine policies.

The intent of the ads was clear to the marketing firms that managed them. WPP’s Gillis, in her remarks to The Drum, said that elevating the brand as part of the vaccine ads was very much the point. “Go to the doctor and ask for ‘Pfizer vaccine,’” she said, discussing the strategy. 

Dini von Mueffling, a New York communications specialist who assisted with many of the Pfizer ads, later discussed the effort with Contagious, another marketing industry publication. The “many legal regulations,” said von Mueffling, “I think ultimately stymie creativity.” But, she added, “we worked within those regulations and were still able to be very creative, which was great.”

Pfizer ran many iterations of its “unbranded” COVID-19 vaccine campaign. The “Because of This” ad campaign featured real people rather than actors answering the question of why they will get vaccinated. “Because this year she turns one, and I’m 74,” the tagline of one Pfizer-sponsored ad read. Another, titled “Hug,” showed two women clutching each other, weeping. “Because you can’t hug a computer screen. Why will you get vaccinated?” the text of the ad asked, in a nod to the lockdown orders. 

Moderna, while operating under the EUA, launched a “Make it Yours” campaign to encourage the use of its vaccine. The company brought on partnerships with the Seattle Seahawks and Boston Red Sox. One of the animated ads featured former Seahawks star Jordan Babineaux, who instructed viewers to “always protect the team” and get vaccinated. “With the vaccines here to help millions, we can take steps towards life as we knew it,” narrated Babineaux.

In other cases, third-party groups funded by Pfizer and Moderna blanketed viewers with ads urging vaccination without any disclaimers. 

Immunize Nevada, a nonprofit that popped up during the pandemic and then disappeared, ran Facebook ads with a doctor imploring viewers to “get vaccinated.” GovVax, another group funded by vaccine industry sources, sponsored social media ads touting vaccines as “free, safe and effective.” The National Hispanic Medical Association, backed by grants from the vaccine pharmaceutical industry, similarly sponsored a “Get Vaccinated” social media campaign. 

NFLPV AP
Former Seattle Seahawk Jordan Babineaux was featured in a Moderna "Make it Yours" vaccine campaign.

Pfizer also tapped the largely unregulated world of influencer marketing. In one instance, the company retained the public relations firm Real Chemistry and an influencer named Darrion Nguyen, who also goes by @Lab_Shenanigans, to create a series of comedic skits mocking vaccine misinformation. The series, titled “I Heard It on the Internet,” mocked critics of vaccine policy as fools who did not follow the science.

Nguyen, who identified himself as a “real life scientist,” produced videos debunking claims such as “vaccines don’t work with Omicron variants” and “vaccines can make you magnetic.” The latter was certainly not true, but the former was up for debate. Research from Israel showed that the Pfizer boosters provided as little as 30% efficacy against the Omicron wave – and other studies suggested at the time that natural immunity provided as much as 87.8% efficacy against the Omicron variant. Those facts were not included in the Pfizer-funded TikTok series. 

The star of the Pfizer social media ads, however, later got into his own misinformation scandal. Earlier this year, Baylor College of Medicine in Texas retracted research authored in part by Nguyen, citing falsified data and fabricated lab results. Nguyen, in response to the news, cited “pressure to meet expectations.”

While few news outlets covered Moderna or Pfizer’s ad campaign at the time, both companies were widely celebrated by marketing professionals for the success of the blitz.

Aaron Kheriaty
Dr. Aaron Kheriaty warns that the money trail is hard to follow in the vaccine industry.

YouGov called Pfizer’s ads the most successful of 2020, while Medical Marketing and Media, an industry group, awarded Moderna, Pfizer, and Johnson & Johnson for their innovative marketing efforts.

Pfizer went so far as to submit a detailed presentation touting the impact of its social media and marketing strategy during the pandemic to the “Shorty Awards,” another industry competition for DTC ads and drug marketing innovation. The video montage of the company’s success shows a series of public relations victories for the industry, including a social media pledge to ensure a safe and effective vaccine, which won Pfizer “positive coverage from almost every top tier [news] outlet,” including the New York Times and Bloomberg. 

The success in selling the public was buoyed by government support. The United States provided at least $31.9 billion in funds for the development, purchasing, and production of the mRNA vaccines, money that padded record profits. Pfizer generated some $37 billion in revenue from the vaccine in 2021, making it one of the most lucrative drug product launches of all time. Moderna, meanwhile, minted four new billionaires as the company’s stock skyrocketed. 

Kheriaty, the bioethicist, is an opponent of all direct-to-consumer ads. But he noted that the vaccine industry campaign appeared particularly pernicious, as government and media voices largely echoed every marketing claim of the vaccine industry with little pushback, while the tens of millions of dollars of pharmaceutical ads provided an inherent conflict of interest for the news programs covering the pandemic. 

“You’re probably just at the tip of the iceberg in terms of tracing the money flow,” Kheriaty sighed.

https://www.realclearinvestigations.com/articles/2024/10/03/nondisclosure_vaccine_ad_blitz_sidestepped_transparency_rules_1062548.html

That ‘70s Show

 A widening war in the Middle East that includes a literally more explosive Iran. Russians and Ukranians killing each other for no reason in a conflict in which the former has threatened a nuclear strike. A belligerent China menacing Taiwan. A dockworker strike (possibly resolved?) that could thrash an economy already ravaged by inflation. A migrant stream that is more invasion than immigration. Rising antisemitism.

Are we back in the 1970s, when the world felt unstable and the future appeared grim?

The words typed above would have not been applicable in late 2019, as Donald Trump was about to complete his third year in office. Then came the novel coronavirus, leading to both economic and political disruption that was not necessary.

America and the world left the ugly 1970s behind when Margaret Thatcher was elected British prime minister in 1979 and Ronald Reagan was elected president in 1980.

The details are different. In the 1970s Americans were ground down by an energy crisis, then-record postwar unemployment, stagflation, political upheaval, societal turbulence and a war that seemed intractable until it was over and then felt like a discouraging loss. There were legitimate concerns that America was losing its status. The Cold War raged and we feared the Soviets would launch nuclear missiles and start a conflict that might finish off all of us.

Our world today is causing similar frustration, uneasiness, and division. All were dropped on us, like a bomb, by the Biden-Harris administration, which has followed the instruction manual of the Obama regime.

Apparently some – maybe close to half of the country – favor, and likely savor, our decline. Polls keep telling us the presidential election is going to be close.

The other half, or so, believes that perpetuating these conditions, in fact, choosing to make them worse, is insane.

Voters have a choice in one month. They can choose concession, to approve the candidates who want the U.S. to be just another country, nothing special, to be a nation of a few elites and a lower class that’s there to serve them. They can send out another Democratic president on another apology tour, invite Washington to increase its influence over our lives, and give censorship and lawfare enormous boosts.

Or they can affirm optimism, energy independence, prosperity across all classes through open markets, an administration that, we hope, will check the federal bureaucracy’s power, and a restoration of patriotism that is unmistakably devoted to American liberty and the ideals of freedom.

Before Britain was turned around by Thatcher, the prime minister was one Sunny Jim Callaghan, who was in reality a rather gloomy chap. The Labour Party prime minister presided over some of the country’s worst of times and, says journalist Mark Steyn, “thought Britain’s decline was irreversible and that the government’s job was to manage it as gracefully as possible.”

The Biden-Harris regime seems to have a similar notion, but rather than merely oversee the fall, it has directed it – and has done so without a shred of grace.

https://issuesinsights.com/2024/10/04/that-70s-show-2/

'Helene Will Send Shockwaves Through the Semiconductor Industry'

 Millions of people across the US South have gone without power or have been forced to evacuate following days of extreme downpours brought on by Hurricane Helene. North Carolina has borne the brunt of the devastation, with the state accounting for a third of all recorded fatalities to date. And as relief operations get underway, the eyes of the world are on a small town of about 2,000 in the western part of the state.

Spruce Pine sits about an hour northeast of Asheville, Mitchell County, and is home to the world’s biggest known source of ultrapure quartz—often referred to as high-purity quartz, or HPQ. This material is used for manufacturing crucibles, on which global semiconductor production relies, as well as to make components within semiconductors themselves.

Semiconductors are the fundamental building blocks of modern IT. Transistors, a type of semiconductor device, are the small electronic switches that perform computation functions in every tech gadget, from smartphones to electric scooters, data centers, and military aircraft. They make possible the processors that power most of the world’s smart gadgets.HPQ is the raw material for the high-grade quartz products that sit at the heart of high-end consumer tech products. Its chemical and physical properties—including high temperature and corrosion resistance, low thermal expansion, high insulation, and light transmission—mean it can be used in optical communication and electronic light sources technology. HPQ drives a $500 billion microchip industry that is core to the $3 trillion global tech sector.

Spruce Pine supplies around 70 percent of the naturally occurring HPQ that is needed for computing devices and products. The site’s market position and significance were underlined in 2019 when a manager for Quartz Corp, one of the two main mining companies that works the deposit, told the BBC: “Inside nearly every cell phone and computer chip you’ll find quartz from Spruce Pine.”

Quartz is the second-most abundant mineral in the Earth’s crust, but while it can be found across the world, quartz reserve properties—

including a deposit’s size and type—vary by region. It is rare to find economically viable deposits of HPQ. Aside from Spruce Pine, the largest are found in India and Brazil.

Another silicon material, so-called silicon metal—a lower-grade and more easily accessible material that is largely sourced in China—is also listed as a critical raw material for the silicon industry by the European Commission, the UK, India, and South Korea. But it is unclear what percentage of it is refined for use in computing. “HPQ from Spruce Pine is, in a way, more critical and valuable because of its purity,” says Jonnie Penn, an associate professor of AI ethics and society at the University of Cambridge.

“Its unique purity emerges out of processes that unfold over geological rather than human timescales,” Penn says. “This purity requirement matters most for advanced computing systems in areas like the military, health care, and quantum computing.”

The two main companies at the Spruce Pine pegmatite complex—roughly 40 kilometers long by 16 kilometers wide, according to a 1962 survey—are Quartz Corp and Unimim, a subsidiary of the global industrial minerals company SCR-Sibelco, based in Belgium.

A spokesperson for Sibelco said, “As of September 26, we have temporarily halted operations at the Spruce Pine facilities in response to these challenges.

“We are working closely with our local team to safely restartperations as soon as we can and are actively coordinating with local authorities and other partners to manage the situation. Our top priority remains the health, safety, and well-being of our employees, as well as ensuring the security of the Spruce Pine facility.”

Quartz Corp did not immediately reply to WIRED’s request for comment.

Viral social media posts have claimed that due to the flooding, global production of semiconductors could halt. This doomsday scenario is unlikely, but experts are gravely concerned about the impact the flooding could have on the tech industry and the economic ramifications of prolonged supply chain pressures caused by the shutdown of the site.

“The key thing will not be just the floods, as bad as they are,” says Chris Hackney, a researcher in human geography at Newcastle University in the UK. “The damage to infrastructure—roads, transport, power, and mining equipment—will stop production for a while. There’s potential for landslides.”

Hackney adds that “any disruption to supply chains will have an impact on prices and production of high-end electronics and tech.”

Tom Bide, a senior scientist at the British Geological Survey, believes it’s possible the disaster will prove minimally disruptive due to stockpiling and other kinds of contingency work.

“The impact on the tech industry will very much depend on how long it takes them to get operations running again,” he says. “It is likely most manufacturers have some level of stockpiles so there will be some ‘slack’ in the system. If the issues are temporary this may have no discernible effect.”

Bide estimates it would take around a month for any serious impacts to be felt.

https://www.wired.com/story/hurricane-helene-shockwaves-semiconductor-industry-microchips-spruce-pine-north-carolina-sand-high-quality-quartz/